Overview
This webinar will cover the history and current status of immunotherapy for treating mesothelioma, and the most pressing unanswered questions in this setting. It will include a bench to bedside review of chemo-immunotherapy in mesothelioma and the potential future of this field.
Activity Objectives:
In this one-hour webinar, Professor Nowak will:
- review the current state-of-the-art for treatment of malignant pleural mesothelioma;
- examine the emerging role of immunotherapy for mesothelioma;
- provide updated results of recently completed studies evaluating new agents and new approaches to the management of malignant mesothelioma; and
- identify the major, ongoing and planned clinical trials most likely to impact patient care in the near future.
- Identify and discuss recent data and current clinical research evaluating the efficacy and safety of immunotherapeutic agents in the treatment of malignant mesothelioma (“MM”).
- Assess those clinical research findings that are most relevant to treating clinicians.
- Appraise the utility of immunotherapy in the management of MM and its evolutionary role in current treatment algorithms.
For any inquiries, please contact meetings@iaslc.org.
- Identify and discuss recent data and current clinical research evaluating the efficacy and safety of immunotherapeutic agents in the treatment of malignant mesothelioma (“MM”).
- Assess those clinical research findings that are most relevant to treating clinicians.
- Appraise the utility of immunotherapy in the management of MM and its evolutionary role in current treatment algorithms.
For any inquiries, please contact meetings@iaslc.org.